The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
from Medical Xpress - latest medical and health news stories https://ift.tt/aHJjYm0
